Titan Medical TMD.TO (TSX) up 2,150% pre-market 13 Mar 2026: volume-driven move

TMD.TO stock opened the pre-market session with a dramatic move, trading at CAD 1.125 after a +2,150.00% intraday change from the prior close of CAD 0.05 on 13 Mar 2026. Volume reached 117,220 shares versus an average of 45,936, flagging this as a high-volume mover on the TSX. The spike closed the intraday range at CAD 1.125 with a year high of CAD 1.25, forcing traders to weigh short-term momentum against valuation and liquidity risks.

TMD.TO stock pre-market price and volume snapshot

Titan Medical Inc. (TMD.TO) is trading at CAD 1.125 pre-market on the TSX, up +2,150.00% from the prior close of CAD 0.05. Reported volume is 117,220 shares, a relative volume of 2.55, which confirms this is a high-volume mover and not routine noise.

Catalysts and news driving TMD.TO stock

Public filings or investor updates commonly drive moves of this size. Market participants are watching Titan Medical’s site and TSX notices for press releases and filings, and we link the company page for direct reference Titan Medical website. At this hour there is no confirmed third-party analyst revision; traders should check official releases and regulatory filings before acting.

Fundamentals and valuation snapshot for TMD.TO stock

Titan Medical lists EPS of -1.73 and a negative trailing PE in the quote feed, though trailing metrics in some datasets show mixed ratios. Market capitalization stands at CAD 128,295,000 with 114,040,000 shares outstanding. Price averages are low: 50-day CAD 0.07 and 200-day CAD 0.07, so the current level is far above historical trading ranges, implying a large valuation gap to normal levels.

Trading metrics and technical context for TMD.TO stock

Key technicals: day low CAD 0.045, day high CAD 1.125, year high CAD 1.25. Average volume is 45,936, so today’s 117,220 is meaningful. Short-term mean reversion risk is high; volume-driven breakouts like this often see rapid profit-taking. Options liquidity is limited, so scalpers and momentum traders should size positions for high volatility and low liquidity.

Meyka AI grade, model forecast and price targets for TMD.TO stock

Meyka AI rates TMD.TO with a score out of 100: 68.67 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month fair-value around CAD 0.30 versus the current CAD 1.125, implying an estimated downside of -73.33%. Forecasts are model-based projections and not guarantees. For scenario planning we offer price targets: base CAD 0.25, bull CAD 0.60, bear CAD 0.05.

Risks and trading strategy for high-volume TMD.TO stock moves

Primary risks: rapid dilution risk, limited liquidity, and headline reversals. Titan Medical operates in Healthcare – Medical Devices, a sector under pressure recently. Active traders should use stop limits, size positions small, and prefer liquidity windows. Longer-term investors must confirm revenue and clinical progress before increasing exposure.

Final Thoughts

TMD.TO stock is a clear high-volume mover this pre-market session on 13 Mar 2026, trading at CAD 1.125 with volume 117,220 versus an average of 45,936. The trade is driven by intraday momentum rather than confirmed upgrades or multiple analyst revisions; that raises the probability of a sharp reversal. Meyka AI rates TMD.TO 68.67 (B, HOLD) after weighing sector performance, key metrics, and growth signals. Our model projects a 12-month fair value near CAD 0.30, implying -73.33% from the current price; forecasts are model-based and not guarantees. Practical takeaways: traders can exploit momentum with tight risk controls and pre-defined exits, while longer-horizon investors should wait for fundamental confirmations such as clear commercial milestones or revenue progress. Check official Titan Medical filings and exchange notices on the TSX before trading, and use Meyka AI’s real-time tools for intraday surveillance and updated metrics.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.